CLIFF (Cordlife Group) Policy Acquisition Expense

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLIFF Cordlife Group Ltd CLIFF
40 GF Score
Price $0.15
GF Value $0.16
! 4 Warning Signs
View Full Analysis

What is Cordlife Group Policy Acquisition Expense?

Policy Acquisition Expense only applies to insurance companies.

CLIFF
40GF Score
Cordlife Group Ltd CLIFF
Policy Acquisition Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cordlife Group (CLIFF) Overvalued in 2026?

Based on GuruFocus' analysis, Cordlife Group stock appears to be undervalued. The current stock price of $0.15 is trading 6% below its estimated GF Value™ of $0.16.

Key valuation signals for CLIFF:

  • Policy Acquisition Expense:
  • GF Value™: $0.16 vs. price of $0.15 (6% below fair value)
  • GF Score™: 40/100 with 4 warning signs

No single metric tells the full story. See the CLIFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cordlife Group Business Description

Other Exchanges P8A:Singapore
Address 1 Kim Seng Promenade, No. 15-01, Great World City East, Singapore, SGP, 237994
Cordlife Group Ltd is a Singapore-based consumer healthcare company focused on cord blood and tissue banking and related diagnostics for families. Its core business is the collection, processing, testing, and cryogenic storage of umbilical cord blood and cord tissue stem cells, sold largely through annual or multi-year storage contracts to parents in Asia. The group also provides diagnostics and screening services, including prenatal and newborn testing, through its diagnostics operations. Its main markets are Singapore, Hong Kong, Malaysia, Indonesia, India, the Philippines, and other parts of Southeast Asia, with Hong Kong and Singapore among its largest revenue contributors. Revenue comes primarily from cord blood banking fees, including initial processing charges and recurring annual storage fees, supplemented by diagnostics testing income. The company operates laboratories and storage facilities in its key markets and markets its services directly to expectant parents, hospitals, and healthcare professionals.
40GF Score

Get the complete analysis for CLIFF

Policy Acquisition Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price
$0.16
GF Value